LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients

• Published in: Leukemia research Vol. 116; p. 106838
• Main Authors: Shehata, Amira M.F., Gohar, Suzy F., Muharram, Nashwa M., Eldin, Samar M. Kamal
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.05.2022
• Subjects: Chronic myeloid leukemia; Humans; Imatinib mesylate; Imatinib Mesylate - therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myeloid, Chronic-Phase - drug therapy; Leukemia, Myeloid, Chronic-Phase - genetics; Leukocytes, Mononuclear - metabolism; Long non-coding RNAs, Polymerase Chain reaction; Prognosis; RNA, Long Noncoding - genetics; Long non-coding RNAs, Polymerase Chain reaction; Prognosis; Chronic myeloid leukemia; Imatinib mesylate

Long noncoding RNAs (lncRNAs) are identified as key players in the initiation, development, and prognosis of chronic myeloid leukemia (CML). Some lncRNAs are expected to serve as diagnostic biomarkers, predictors of clinical outcomes and therapeutic targets. We aimed to examine the expression of lnc...